lopinavir and ritonavir, Kaletra
GENERIC NAME: lopinavir and ritonavir
BRAND NAME: Kaletra
DRUG CLASS AND MECHANISM: Kaletra is an oral medication that is a combination of lopinavir and ritonavir. It is used for treating infections with the
human immunodeficiency virus (HIV). It is in a class of drugs called protease inhibitors which also includes ritonavir
(Norvir),
nelfinavir (Viracept) and saquinavir (Invirase, Fortovase). Although both lopinavir and ritonavir inhibit the HIV virus, they are combined in
Kaletra because ritonavir increases the concentration of lopinavir in the body. In fact, the activity of
Kaletra against HIV is due to the lopinavir because the amount of ritonavir in Kaletra is not enough to inhibit the HIV virus. During infection with HIV, the HIV virus multiplies within the
body's cells. Viruses are released from the cells and spread throughout the body where they infect other cells. In this manner, HIV
infection is perpetuated among new cells that the body produces continually. During the production of the viruses, new proteins for the viruses are
made. Some of the proteins are structural proteins, that, is, proteins that form the body of the virus. Other proteins are enzymes which
manufacture DNA and other components for the new viruses. Protease is the enzyme that forms the new structural proteins and enzymes. The lopinavir in
Kaletra blocks the action of protease and results in the formation of defective viruses that are unable to infect the body's cells. As a result, the number of viruses in the body (the viral load) decreases. Nevertheless,
Kaletra does not prevent the
transmission of HIV among individuals, and it does not cure HIV infections or AIDS.
Kaletra was approved by the FDA in September, 2000.
GENERIC AVAILABLE: No
PRESCRIPTION: Yes
PREPARATIONS: Tablets:
100mg lopinavir and 25 mg ritonavir (100/25), 200 mg lopinavir and 50 mg
ritonavir (200/50). Oral solution: 80 mg lopinavir and 20 mg ritonavir per mL (80/20 mg/mL).
STORAGE: Capsules and solution should be refrigerated at 2-8°C (36-46°F). If stored at room temperature, the capsules and solution should be used within 2 months.
PRESCRIBED FOR: Kaletra is used for the treatment of HIV infection.
DOSING: Kaletra may be
administered with or without food.
Therapy-naive adult patients: 200/50 tablets, two twice daily or four, once
daily; Oral solution, 5 mL twice daily or 10 mL once daily with food.
Therapy-experienced adult patients: (Once daily administration of
Kaletra is not recommended.) 200/50 tablets, two twice daily; Oral
solution 5 mL twice daily.
Childrenbetween 6 monthsand 18 years of age: The
recommended dose is 230/57.5 mg/m2 given twice daily and not to exceed the
recommended adult dose.. Kaletra should not be administered once daily in
patients less than 18 years of age.
In combination with efavirenz, nevirapine, (fos)amprenavir or
nelfinavir: Once daily administration is not recommended when combined
with efavirenz, nevirapine, (fos)amprenavir or nelfinavir. Adults:
Tablets, two 200/50 tablets and one 100/25 tablet twice daily; Oral solution,
6.5 mL twice daily.For children the recommended dose is 300/75 mg/m2
not to exceed the adult dose.
DRUG INTERACTIONS: Kaletra interacts with many drugs. Some of the important interactions are mentioned
below. Viewers should consult their healthcare provider before combining any drug with
Kaletra.
Kaletra should not be used together with amiodarone
(Cordarone), quinidine (Quinaglute, Cardioquin), triazolam (Halcion), midazolam
(Versed), pimozide (Orap), ergotamine derivatives (e.g. Ergostat), propafenone
(Rythmol) and flecainide (Tambocor) because Kaletra increases the levels of these drugs in the body and as a result may lead to
serious adverse effects of these drugs
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
|
Back to Medications Index